Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Beule, Dieter Dr. (6) Blankenstein, Thomas Prof. Dr. (179) Bunse, Mario Dr. (3) Cakmak-Görür, Nese Dr. (1) Clauß, Julian (1) Daniel, Peter Prof. Dr. (4) Dyck, Lydia Dr. (1) Filosa, Alessandro Dr. (1) Gerhardt, Holger Prof. Dr. (1) Henssen, Anton Prof. Dr. med. (1) Höpken, Uta Elisabeth PD Dr. (2) Hübner, Norbert Prof. Dr. (1) Ivics, Zoltan Dr. (1) Izsvak, Zsuzsanna Dr. (1) Jeuthe, Sarah Dr. (1) Kammertöns, Thomas Dr. (38) Kopp, Joachim Dr. (5) Kühn, Ralf Dr. (1) Kunz, Severine Dr. (1) Lorenz, Felix Dr. (1) Marko, Lajos Dr. (1) Mertins, Philipp Dr. (3) Na, Il-Kang Dr. (2) Nguyen, Tam Hoai Dr. (1) Obermayer-Wasserscheid, Benedikt Dr. (1) Patone, Giannino Dr. (1) Pezzutto, Antonio Prof. Dr. (17) Popp, Oliver Dr. (3) Rahn, Hans-Peter Dr. (1) Rathjen, Fritz Prof. Dr. (1) Rehm, Armin Dr. (1) Rhein, Simone Dr. (2) Richter, Matthias (1) Rosenberger, Leonie Milena (1) Sawamiphak, Suphansa Dr. (1) Schlag, Peter M. Prof. Dr. (1) Schmitt, Clemens Prof. Dr. (1) Schütz, Anja Dr. (1) Siffrin, Volker (1) Sporbert, Anje Dr. (1) Stein, Ulrike Prof. Dr. (3) Uckert, Wolfgang Prof. Dr. (23) Walther, Wolfgang Prof. Dr. (7) Willimsky, Gerald Dr. (34) Wolf, Susanne Dr. (2) (-) Leisegang, Matthias Prof. Dr. rer. nat. (10) 2006 (1) 2010 (1) 2011 (1) 2015 (2) 2016 (1) 2017 (1) 2018 (1) 2020 (1) 2022 (1) AG Müller/Dechend (ECRC) (4) Animal Phenotyping (1) Cardiac MRI (4) Chemical Biology (3) Developmental Biology / Signal Transduction (1) Genetics and Genomics of Cardiovascular Diseases (2) Genetics of Congenital Heart Disease (1) Hypertension-caused End-Organ Damage (4) Hypertension-Mediated End-Organ Damage (4) Integrative Vascular Biology (1) Molecular Biology of Peptide Hormones (2) (-) Molecular Immunology and Gene Therapy (10) Nephrology and Inflammatory Vascular Diseases (3) Screening Unit (3) Translational Bioinformatics (1) 10 Results: Active Filter: Leisegang, Matthias Prof. Dr. rer. nat.Molecular Immunology and Gene Therapy Sort: Result score Newest to oldest Oldest to newest November, 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert April 15, 2010 / Clin Cancer Res T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy M. Leisegang A. Turqueti-Neves B. Engels T. Blankenstein D.J. Schendel W. Uckert E. Noessner July 28, 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein August, 2018 / Clin Cancer Res Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus I. Gavvovidis M. Leisegang G. Willimsky N.J. Miller P. Nghiem T. Blankenstein May 04, 2017 / Nature Tumour ischaemia by interferon-γ resembles physiological blood vessel regression T. Kammertoens C. Friese A. Arina C. Idel D. Briesemeister M. Rothe A. Ivanov A. Szymborska G. Patone S. Kunz D. Sommermeyer B. Engels M. Leisegang A. Textor H.J. Fehling M. Fruttiger M. Lohoff A. Herrmann H. Yu R. Weichselbaum W. Uckert N. Hübner H. Gerhardt D. Beule H. Schreiber T. Blankenstein April, 2015 / Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber April, 2015 / Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein March 01, 2016 / J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein February 07, 2020 / EMBO Mol Med "Designer cytokines" targeting the tumor vasculature - think global and act local T. Kammertoens J. Kemna M. Leisegang August, 2022 / Cytotherapy Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy M.F. Lammoglia Cobo C. Welters L. Rosenberger M. Leisegang K. Dietze C. Pircher L. Penter R. Gary L. Bullinger A. Takvorian A. Moosmann K. Dornmair T. Blankenstein T. Kammertöns A. Gerbitz L. Hansmann
November, 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
April 15, 2010 / Clin Cancer Res T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy M. Leisegang A. Turqueti-Neves B. Engels T. Blankenstein D.J. Schendel W. Uckert E. Noessner
July 28, 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
August, 2018 / Clin Cancer Res Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus I. Gavvovidis M. Leisegang G. Willimsky N.J. Miller P. Nghiem T. Blankenstein
May 04, 2017 / Nature Tumour ischaemia by interferon-γ resembles physiological blood vessel regression T. Kammertoens C. Friese A. Arina C. Idel D. Briesemeister M. Rothe A. Ivanov A. Szymborska G. Patone S. Kunz D. Sommermeyer B. Engels M. Leisegang A. Textor H.J. Fehling M. Fruttiger M. Lohoff A. Herrmann H. Yu R. Weichselbaum W. Uckert N. Hübner H. Gerhardt D. Beule H. Schreiber T. Blankenstein
April, 2015 / Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
April, 2015 / Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
March 01, 2016 / J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein
February 07, 2020 / EMBO Mol Med "Designer cytokines" targeting the tumor vasculature - think global and act local T. Kammertoens J. Kemna M. Leisegang
August, 2022 / Cytotherapy Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy M.F. Lammoglia Cobo C. Welters L. Rosenberger M. Leisegang K. Dietze C. Pircher L. Penter R. Gary L. Bullinger A. Takvorian A. Moosmann K. Dornmair T. Blankenstein T. Kammertöns A. Gerbitz L. Hansmann